(Q36899073)

17 August 2017

1 reference

title

Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis (English)

1 reference

17 August 2017

0 references

1 reference

Zhou Xing

1

1 reference

17 August 2017

Thomas James Charters

series ordinal

2

1 reference

17 August 2017

publication date

1 August 2007

1 reference

Expert Review of Vaccines

17 August 2017

published in

1 reference

17 August 2017

volume

6

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

539-546

1 reference

Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Prime-boost immunisation strategies for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Advances in tuberculosis vaccine strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Tuberculosis vaccines: the past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Tuberculosis vaccines: current progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Vaccination of cattle with a CpG oligodeoxynucleotide-formulated mycobacterial protein vaccine and Mycobacterium bovis BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Should a new tuberculosis vaccine be administered intranasally?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Vaccination of the brushtail possum (Trichosurus vulpecula) against Mycobacterium bovis infection with bacille Calmette-Guérin: the response to multiple doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Bacillus Calmette-Guérin revaccination questionable with low tuberculosis incidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

How can immunology contribute to the control of tuberculosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Tuberculosis vaccine development; from mouse to man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Boosting vaccine for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Determinants of vaccine-induced resistance in animal models of pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

On the use of DNA vaccines for the prophylaxis of mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Improved tuberculosis DNA vaccines by formulation in cationic lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Adenoviral vectors: a promising tool for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Adenoviruses as vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Adenoviral vectors for mucosal vaccination against infectious diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing Mycobacterial antigen 85A and Mycobacterium bovis BCG

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

Tuberculosis subunit vaccine development: on the role of interferon-γ

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.539

21 January 2018

Identifiers

DOI

10.1586/14760584.6.4.539

1 reference

17 August 2017

1 reference